1. Estimated projection of US cancer incidence and death to 2040;Rahib;JAMA Netw Open,2021
2. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial;Conroy;JAMA Oncol,2022
3. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial;Neoptolemos;Lancet Lond Engl,2017
4. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - a pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials;Kurreck;Eur J Cancer Oxf Engl. 1990,2021
5. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial;Jones;JAMA Surg,2019